Ruxolitinib

證據等級: L5

預測適應症: 10 個

Ruxolitinib: From Myeloproliferative Neoplasms to Infection-Associated Hemophagocytic Syndrome

One-Sentence Summary

Ruxolitinib is a JAK1/2 inhibitor; its Taiwan regulatory record in this evidence pack is empty (not currently marketed here), though it is publicly known to be approved abroad for myelofibrosis, polycythemia vera, and steroid-refractory GVHD. Among 10 TxGNN-predicted indications in this pack, hemophagocytic syndrome associated with an infection has by far the most mature evidence base — 1 completed-enrollment Phase 3 RCT, 1 upcoming Phase 1 trial, and 20 supporting publications (including a prospective pediatric cohort and preclinical mechanism studies) — earning a Proceed with Guardrails recommendation, well ahead of the other 9 candidates which remain at Hold (L5, no clinical/literature support).

Quick Overview

Item	Content
Original Indication	Not recorded in this evidence pack (data gap — see DG001/DG002); publicly documented original indications include myelofibrosis, polycythemia vera, and acute/chronic graft-versus-host disease
Predicted New Indication	Hemophagocytic syndrome associated with an infection
TxGNN Prediction Score	99.32% (global rank 15,356)
Evidence Level	L2
US Market Status	✗ Not Marketed (0 licenses on file)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Screening Context: Why This Indication Over the TxGNN #1 Ranked Candidate

The single highest-scoring TxGNN prediction in this pack (uterine corpus PEComa, 99.73%) and most of the next eight candidates (PEComa family, lymphangioleiomyomatosis, liposarcoma, familial rhabdoid tumor) have no supporting clinical trials or literature, and several carry explicit mechanistic red flags — these tumor families are driven by mTOR or SWI/SNF pathway alterations, not JAK-STAT signaling, so a JAK1/2 inhibitor has weak biological rationale there. All are scored L5/Hold.

By contrast, two hemophagocytic lymphohistiocytosis (HLH)-related candidates in the same pack are directly consistent with ruxolitinib’s known pharmacology (IFN-γ/JAK-STAT pathway blockade), and one of them — infection-associated HLH — has actual trial and cohort-level evidence. This report therefore focuses on that indication as the clinically actionable candidate.

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for ruxolitinib is not available in this evidence pack (data gap DG002). Based on generally known pharmacology, ruxolitinib is a JAK1/2 inhibitor whose efficacy in myeloproliferative neoplasms and steroid-refractory GVHD stems from suppressing pathologic cytokine signaling through the JAK-STAT pathway.

HLH — including the infection-triggered subtype — is pathophysiologically defined by an IFN-γ–driven cytokine storm that signals almost exclusively through JAK1/2-STAT1. This gives ruxolitinib strong mechanistic plausibility here, and the parallel is not purely theoretical: murine-model studies in the evidence pack (PMID 31015190, 32530039, 37228616) directly demonstrate that ruxolitinib dampens IFN-γ/JAK-STAT-driven T-cell hyperactivation and immunopathology in HLH models, and a prospective pediatric cohort (PMID 35344583) has already used ruxolitinib response as the basis for stratified frontline HLH treatment.

The evidence is still short of definitive: the one Phase 3 RCT directly testing ruxolitinib in this population (NCT04424056, COVID-19-associated HLH-spectrum disease) has an unknown/unreported status, so a completed, reported Phase 2/3 RCT is not yet in hand — consistent with the assigned L2 rather than L1 evidence level.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04424056	Phase 3	Unknown (not confirmed completed)	216	Randomized trial of Anakinra or Tocilizumab, alone or combined with ruxolitinib, in severe stage 2b–3 COVID-19-associated hyperinflammatory disease (CRP >200 mg/L, ARDS risk). Results not yet publicly reported.
NCT07424222	Phase 1	Not yet recruiting	16	Pilot safety/efficacy study of oral ruxolitinib for Immune Effector Cell-Associated HLH-like Syndrome (IEC-HS) following CAR-T therapy; also assessing dosing duration and biomarkers of response.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35344583	2022	Prospective cohort (n=51)	Blood	Ruxolitinib used as first-line agent for pediatric HLH with response-based stratified treatment; registered prospective trial (ChiCTR2000031702).
37787838	2023	Cohort/case series (n=12)	Annals of Hematology	Sintilimab combined with ruxolitinib as compassionate therapy for adult EBV-associated HLH.
40665481	2025	Cohort (n=53 vs 42)	British Journal of Haematology	Ruxolitinib-based regimen compared with adjusted HLH-94 chemotherapy in pediatric EBV-HLH; efficacy and safety analysis.
38691058	2024	Case series	J Pediatr Hematol Oncol	Emapalumab + ruxolitinib + dexamethasone effective in EBV-HLH with multiorgan damage and severe infection.
34605776	2022	Consensus guideline	Critical Care Medicine	Consensus-based guidelines for recognition, diagnosis, and management of HLH in critically ill children and adults.
31015190	2019	Mechanistic (murine model)	Blood	Establishes that ruxolitinib inhibits IFN-γ downstream signaling and lessens inflammation in a perforin-deficient/LCMV HLH mouse model.
32530039	2020	Mechanistic	Blood	JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in cytokine storm syndromes including HLH.
37228616	2023	Mechanistic (mouse model)	Frontiers in Immunology	Characterizes cellular/transcriptional effects of JAK and/or IFN-γ inhibition in a primary HLH mouse model.
36263041	2022	Case report	Frontiers in Immunology	Ruxolitinib used as first-line therapy for secondary HLH in a patient with AIDS.
31879790	2020	Cohort (n=12)	Annals of Hematology	Ruxolitinib for steroid-refractory acute GVHD in HSCT patients with concurrent EBV-associated HLH.

Safety Considerations

No key warnings, contraindications, or drug-drug interaction data are available in this evidence pack (DG001, flagged Blocking). Please refer to the package insert for safety information once available.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Infection-associated HLH has strong mechanistic support (IFN-γ/JAK-STAT-driven cytokine storm, directly validated in preclinical HLH models) and an active, if still maturing, clinical evidence base — including one Phase 3 RCT of unreported status and a growing body of cohort/case-series data — but no completed, reported randomized trial yet confirms efficacy in this specific population.

To proceed, the following is needed:

TFDA label data (warnings, contraindications) — currently a Blocking gap (DG001) that must be resolved before any safety pre-assessment (S1)
Confirmed mechanism-of-action documentation from DrugBank (DG002)
Outcome data from NCT04424056 once reported, to determine whether L1 evidence threshold is met
Monitoring of NCT07424222 (Phase 1, not yet recruiting) for emerging safety/efficacy signals in the related IEC-HS population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.